Drug dramatically reduces risk of dangerous blood clots in cancer patients

December 4, 2018, The Ottawa Hospital
Drug dramatically reduces risk of dangerous blood clots in cancer patients
Blood clots in the legs can cause swelling, redness and pain. If a clot forms in the lungs, it can be deadly. New research provides the first approach for safely preventing these clots in people with cancer. Credit: The Ottawa Hospital

A Canadian clinical trial published in the New England Journal of Medicine provides the first approach for safely preventing blood clots (or venous thromboembolism) in people with cancer. About half of people newly diagnosed with a solid cancer could be candidates for the strategy, which involves a low dose of a direct oral anticoagulant called apixaban.

"Cancer increases the risk of , which in turn can cause pain, reduce quality of life and increase the risk of death," said senior author Dr. Philip Wells, a hematologist, senior scientist and Chief of Medicine at The Ottawa Hospital and the University of Ottawa. "Our study shows for the first time that we can safely prevent these clots in many people with cancer."

A key part of the study was the identification of cancer patients with a higher risk of developing clots. This was done using the Khorana score, which is based on blood tests results and other clinical factors. The researchers found that about half of all people starting cancer chemotherapy were in the higher risk group. They enrolled 563 of these patients from 13 Canadian centres in the trial and randomly assigned them to receive apixaban (2.5 mg twice a day for six months) or a placebo.

Of the 275 patients in the placebo group, 28 suffered a blood within six months (10.2 percent) compared to 12 of 288 in the apixaban group (4.2 percent). The researchers also looked at side effects related to bleeding, as these are known to increase with the use of anticoagulants. Three patients in the placebo group suffered a major bleed (1 percent) compared to six patients in the apixaban group (2.1 percent), but all bleeds were treatable.

"Anticoagulants are commonly used to prevent blood clots in other high-risk groups, but the traditional thinking has been that these drugs would cause too much bleeding in people with cancer," said first author Dr. Marc Carrier, a hematologist, senior scientist and associate professor at The Ottawa Hospital and the University of Ottawa. "Our study shows that if you select the right patients and use a relatively low dose of a direct oral anticoagulant, the benefits easily outweigh the risks."

With about 1.9 million people diagnosed with cancer every year in Canada and the U.S., the researchers estimate that about half, or 950,000 could be considered for the blood clot prevention strategy tested in the study. In this population, the strategy would be expected to prevent clots in six percent, or 57,000 people. The preventative strategy would also save money, as treating blood clots can be very expensive.

This research means a lot to Harold Black, 76, who developed a -associated blood clot in his lungs (pulmonary embolism) in September 2018. The large clot required two days of treatment and monitoring at The Ottawa Hospital, followed by ongoing daily heparin injections in the belly.

"I feel very lucky because I was told that the first sign of a pulmonary embolism is often death," said Black. "If this research prevents people like me from developing blood clots, that will make a big difference for a lot of people."

The blood clot (thrombosis) program at The Ottawa Hospital and the University of Ottawa is the largest and the most research-intensive in the world. With four publications in the New England Journal of Medicine since 2015, their research is transforming lives both in Ottawa and around the world.

"I want to thank the outstanding physicians, nurses, research coordinators and other members of our thrombosis team," said Dr. Wells. "But above all, I want to thank our patients for participating in our research and helping us improve care for them and others around the world."

This study was sponsored by the Ottawa Hospital Research Institute, with funding primarily from the Canadian Institutes of Health Research. The BMS-Pfizer Alliance also provided funding but had no role in designing the study or analyzing the results. The study was also supported by the CanVECTOR research network and the Ottawa Methods Centre. Research at The Ottawa Hospital is possible because of generous donations to The Ottawa Hospital Foundation.

Explore further: Rivaroxaban reduced blood clots and related death in cancer patients

More information: Marc Carrier et al, Apixaban to Prevent Venous Thromboembolism in Patients with Cancer, New England Journal of Medicine (2018). DOI: 10.1056/NEJMoa1814468

Related Stories

Rivaroxaban reduced blood clots and related death in cancer patients

December 4, 2018
Cleveland Clinic medical oncologist and researcher, Alok Khorana, M.D., is the primary investigator on a study that concluded rivaroxaban for venous thromboembolism (VTE), a blood clot in the venous system, significantly ...

Researchers say oral apixaban safe and effective for treating blood clots in cancer patients

December 3, 2018
Mayo Clinic researchers have found that an oral drug, apixaban, used to treat blood clots in patients undergoing cancer therapy, is safe and effective. The drug was associated with fewer major bleeding events and fewer recurrent ...

Extended use of oral anticoagulant after hospital discharge reduces non-fatal blood clots

August 26, 2018
The use of an oral anticoagulant medicine in medically ill patients for 45 days following their discharge from the hospital reduces the rate of non-fatal symptomatic blood clots with no impact on fatal blood clots, according ...

Over 10,000 Canadian women per year can stop taking blood thinners for unexplained clots

April 4, 2017
A Canadian-led research group has developed and validated a rule that could let half of women with unexplained vein blood clots stop taking blood thinners for life. These findings were published in The BMJ.

Study could reduce unnecessary cancer screening

June 22, 2015
A large clinical trial led by researchers at The Ottawa Hospital and the University of Ottawa has found that contrary to expectations, a CT scan of the abdomen and pelvis does not improve cancer detection in people with unexplained ...

New blood thinner better at preventing recurrent blood clots than aspirin

March 19, 2017
An international research team with prominent Canadian leadership has found that the blood thinner rivaroxaban is as safe as aspirin, and more effective at preventing recurrence of life-threatening blood clots in the legs ...

Recommended for you

Treatment shown to improve the odds against bone marrow cancer

December 15, 2018
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.